Check 35,000+ stocks against 26 valuation models and 37 quality factors

BioHarvest Sciences Inc. (BHST) fair value: what the stock is really worth

As of Oct 13, 2026: fair value of BioHarvest Sciences Inc. $0.31, price $1.82, upside -82.7%, quality 35 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? No
Add to watchlist

Consumer Defensive · US · Based in Canada · ISIN CA09076J2074

Thin data Oct 2, 2026

BioHarvest Sciences Inc.

BHST · US

Weakest SetupStrongly overvalued and low quality.

Our calculation puts a fair price 83% below what the stock costs today.

Low debt

Expensive Growth (revenue 5y +144.4 %/yr in USD)

Fair value $0.3145 · Strongly overvalued (−82.7%)

Quality 35/100

Loss-making · -31.2% net margin (TTM)

Negative free cash flow

Trails peers (0/10)

Narrow moat 9/100 · thin data

Thin data

⚠ Dilution

26 models, one by oneBear $0.2040 to bull $0.3910 Growth analysisrevenue history, year by year Quality 35/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch BioHarvest Sciences Inc. Common Stock for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.

How to read this chart

23‑month range $1.45 – $12.65 · fair‑value band $0.2040 – $0.3910 · the $1.82 price screens above the $0.3145 fair value. Dashed = 300-day average. As of Oct 2, 2026.

Follow BioHarvest Sciences Inc. Common Stock in your weekly email

Every Wednesday you see whether BioHarvest Sciences Inc. Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through two segments: Products and CDMO Services. The company develops botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, marketing, and sale of science-based health and wellness nutraceutical solutions that are manufactured and sold as dietary supplements and functional food and beverages, as well as the manufacturing, marketing, and sale of science-based health, pharmaceutical, and cosmeceutical solutions. The company also provides contract development and manufacturing operation services. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red wine. The company has a strategic collaboration with Tate & Lyle plc for the development of plant-based sweetener molecules. The company is based in Vancouver, Canada.

Stock analysis

BioHarvest Sciences Inc. Common Stock (BHST) currently trades at $1.82, while our model-based Fair Value estimate is $0.3145, 82.7% below the price, so the stock looks overvalued today.

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

Scenario range: $0.2040 (bear) to $0.3910 (bull), the price of $1.82 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Consumer Defensive sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

BioHarvest Sciences Inc. Common Stock reported revenue of $34.5M in FY2025 versus $2.1M in FY2021, a compound +101.3%/yr. Reported net income was −$11.1M in FY2025.

Key figures

Market cap $41.3M · P/S ratio 0.95 · EPS (TTM) $−0.5000 · Net margin −32.3% · Return on equity −143% · Return on assets (EBIT) −60.4% · Operating margin −28.4% · Revenue (TTM) $35.5M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (low confidence).

What moves the price

The share trades about 86% below its 52-week high and 26% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Consumer Defensive peers we cover trades at 6% fair-value upside, at −83%, BHST screens richer than that median.

Fair Value models

Bear $0.2040 Fair Value $0.3145 Bull $0.3910

Price $1.82 · Upside -82.7%

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

NCAV (Graham) $0.5600 $0.7500 $1.12 54

All 1 models by family

Asset-Based

NCAV (Graham) $0.5600 $0.7500 $1.12 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 35/100

Of which business quality 35 · Market factors (momentum, volatility) 6

Profitability 26

Margins and returns on capital today

Quality Growth 78

Are margins and returns improving?

Cashflow 3

Earnings quality: real cash, not paper profit

Fin. Strength 69

Balance sheet, leverage, solvency risk

Investment 37

Disciplined investing over empire-building

Low Volatility 17

Calm price path (market factor)

Momentum 2

Price trend over the last 3–12 months (market factor)

52W Momentum 2

Distance to the 52-week high (market factor)

Net Issuance 0

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100

The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Revenue growth 1 year

+37.0%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+84.5%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+144.4%

Start year 2020 (pandemic)

Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+132.6%

’19

’20

’21

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

−1,557.1% (2020) → −16.2% (2025)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

BHST screens overvalued: fair value 83% below the price. Compare with Nestlé S.A →

Compare BioHarvest Sciences Inc. Common Stock with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 633 stocks

Beats the industry median on 0/9 measures

Overall it trails its industry peers.

Valuation

Quality Score 35 · Bottom 25%

Fair Value upside −82.7% · Bottom 25%

Profitability

Return on assets −11.0% · Bottom 25%

Net margin (TTM) −31.2% · Bottom 25%

Operating margin (TTM) −28.4% · Bottom 25%

Growth and dividend

Revenue growth 3.8% · Below median

Balance sheet

Debt / equity 0.10× · Above median

Valuation Multiplesvs Packaged Foods median · lower = cheaper

P/B 1.62× · Pricier than median

P/S (TTM) 1.16× · Pricier than median

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 34

FUTURE (revenue growth)19 · sector 23

PAST (return on equity)0 · sector 31

HEALTH (low debt)95 · sector 96

DIVIDEND (yield)0 · sector 58

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Packaged Foods stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value	Compare
Inner Mongolia Yili Industrial Group 600887	¥27.96	¥41.84	+50%	vs BHST
Wilmar International Limited F34	3.46 SGD	5.15 SGD	+49%	vs BHST
The Kraft Heinz Company KHC	$22.45	$29.20	+30%	vs BHST
Foshan Haitian Flavouring and Food Company 603288	¥33.89	¥37.28	+10%	vs BHST
General Mills, Inc GIS	$32.59	$34.59	+6%	vs BHST
Danone S.A BN	€59.28	€50.65	−15%	vs BHST
Nestlé S.A NESN	CHF 75.20	CHF 59.51	−21%	vs BHST
Kerry Group KRZ	€88.70	€59.96	−32%	vs BHST
Nestlé India Limited NESTLEIND	₹1,325	₹724.74	−45%	vs BHST
Yihai Kerry Arawana Holdings 300999	¥25.56	¥9.98	−61%	vs BHST

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator P/E Ratio Calculator PEG Ratio Calculator Graham Number Peter Lynch Formula DDM Calculator Intrinsic Value Intrinsic vs Extrinsic Value P/E Ratio by Sector

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

BioHarvest Sciences Inc. Common Stock · Fair Value
$0.3145 −83%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/BHST" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">BioHarvest Sciences Inc. Common Stock · Fair Value</span><br><b style="font-size:20px">$0.3145</b> <span style="color:var(--red);font-weight:700;font-size:14px">−83%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "BioHarvest Sciences Inc. Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/BHST

Frequently asked questions

Is BioHarvest Sciences Inc. (BHST) overvalued or undervalued?

As of Oct 2, 2026, our model estimates a fair value of $0.3145 versus a price of $1.82, about −83% upside (overvalued).

What is the fair value of BHST?

Our model-based fair value for BioHarvest Sciences Inc. Common Stock is $0.3145 (as of Oct 2, 2026), built from audited fundamentals. The current price: $1.82.

What is the quality score of BHST?

BioHarvest Sciences Inc. Common Stock has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for BioHarvest Sciences Inc. (BHST)?

Our model-based price target is the fair value of $0.3145 (as of Oct 2, 2026) from 1 valuation models. Cautious scenario $0.2040, optimistic scenario $0.3910. It is a calculation from audited fundamentals, not an analyst target.

What is the BioHarvest Sciences Inc. Common Stock stock forecast for 2026?

Our models put fair value at $0.3145, about −83% upside versus a price of $1.82 (overvalued). Cautious scenario $0.2040, optimistic scenario $0.3910. The calculation is refreshed regularly with new filings.

What is the revenue of BioHarvest Sciences Inc. (BHST)?

BioHarvest Sciences Inc. Common Stock reported trailing-twelve-month revenue of about $35.5M (latest available figure, as of Oct 2, 2026).

What is the intrinsic value of BioHarvest Sciences Inc. (BHST)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BioHarvest Sciences Inc. Common Stock it is $0.3145 per share (as of Oct 2, 2026), against a price of $1.82. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).

Is BioHarvest Sciences Inc. Common Stock stock overvalued or undervalued in 2026?

As of Oct 2, 2026, BHST trades above its calculated fair value: price $1.82, fair value $0.3145, a gap of about −83% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of BHST?

No. The price is what the market pays today ($1.82); the fair value is what the company's own numbers justify ($0.3145). For BioHarvest Sciences Inc. Common Stock the two are $1.51 per share apart. That gap is exactly why we show both numbers side by side.

How much is BioHarvest Sciences Inc. Common Stock worth?

The market values BioHarvest Sciences Inc. Common Stock at about $41.3M (market capitalisation, as of Oct 2, 2026). Per share that is $1.82; our models calculate a fair value of $0.3145 per share.

What do the bullish and bearish scenarios say about BHST?

Our models span a range for BioHarvest Sciences Inc. Common Stock: cautious scenario $0.2040, base $0.3145, optimistic $0.3910 per share (as of Oct 2, 2026, price $1.82). The range comes from different growth and margin assumptions, not from analyst opinions.

How solid is the balance sheet of BioHarvest Sciences Inc. (BHST)?

Balance-sheet figures for BioHarvest Sciences Inc. Common Stock (as of Oct 2, 2026): return on equity −142.5%, debt of 0.10 per unit of equity. They feed the Quality Score of 35/100, which measures business quality independently of the share price.

How far is BHST from its 52-week high?

BioHarvest Sciences Inc. Common Stock trades at $1.82, about 86% below its 52-week high of $12.65 and 26% above the low of $1.45 (as of Oct 13, 2026). Distance from the high says nothing about value: that is what the fair value of $0.3145 is for.

Which stocks are comparable to BioHarvest Sciences Inc. Common Stock?

From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, Foshan Haitian Flavouring and Food Company, The Kraft Heinz Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is BioHarvest Sciences Inc. Common Stock stock attractive at the current price?

The data as of Oct 2, 2026: price $1.82, calculated fair value $0.3145 (−83%), Quality Score 35/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of BHST calculated?

We run BioHarvest Sciences Inc. Common Stock through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.3145, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. BioHarvest Sciences Inc. Common Stock itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of BioHarvest Sciences Inc. (BHST)?

The closing price on Oct 13, 2026 was $1.82. Our model-based fair value is $0.3145, about −83% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with BioHarvest Sciences Inc. Common Stock right now?

The price sits above even our optimistic bull case ($0.3910). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.2040 to $0.3910) leaves room in how you read the outcome.

Key figures of BioHarvest Sciences Inc. Common Stock

How large is the market capitalisation of BioHarvest Sciences Inc. (BHST)?

The market capitalisation of BioHarvest Sciences Inc. Common Stock is $41.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of BioHarvest Sciences Inc. (BHST)?

The price-to-sales ratio of BioHarvest Sciences Inc. Common Stock is 0.95 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of BioHarvest Sciences Inc. (BHST)?

Earnings per share at BioHarvest Sciences Inc. Common Stock are $−0.5000. Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of BioHarvest Sciences Inc. (BHST)?

The net margin of BioHarvest Sciences Inc. Common Stock is −32.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of BioHarvest Sciences Inc. (BHST)?

The return on equity (ROE) of BioHarvest Sciences Inc. Common Stock is −143% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of BioHarvest Sciences Inc. (BHST)?

On an EBIT basis the return on assets of BioHarvest Sciences Inc. Common Stock is −60.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of BioHarvest Sciences Inc. (BHST)?

The operating margin of BioHarvest Sciences Inc. Common Stock is −28.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at BioHarvest Sciences Inc. (BHST)?

Revenue at BioHarvest Sciences Inc. Common Stock is growing +3.8% versus a year earlier (3y avg +84.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How much free cash flow does BioHarvest Sciences Inc. (BHST) generate?

The free cash flow of BioHarvest Sciences Inc. Common Stock is −$9.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net cash does BioHarvest Sciences Inc. (BHST) hold?

BioHarvest Sciences Inc. Common Stock holds more cash than debt, $8.9M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch BioHarvest Sciences Inc. Common Stock in the live analysis

One click puts BioHarvest Sciences Inc. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.